Associated tags: Intelligence, Proximity, Drug discovery, Protein, Pharmaceutical industry, ML, Health, Biotechnology, Science, Artificial Intelligence, Pharmaceutical
Locations: BERLIN, UNITED STATES, NORTH AMERICA, NEW YORK, SEOUL, CHICAGO, MASSACHUSETTS
Technology,
Research,
Health Technology,
Biotechnology,
Health,
Pharmaceutical,
Other Science,
Science,
Artificial Intelligence,
University,
Machine learning,
Therapy,
Microbiology,
Member,
MIT,
GSK,
Publication,
Harvard University,
Growth,
Harvard Medical School,
Drug discovery,
Organic chemistry,
Merck,
TPD,
SAB,
DRS,
Multimedia,
PROTAC,
Proteolysis targeting chimera,
Medical device VantAI , a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).
Key Points:
- VantAI , a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).
- Pentelute and Churcher join an existing SAB comprising experts in protein design, whole-proteome structural interactomics, and generative AI for small molecule drug design.
- Photo credit: VantAI
“We are pleased to welcome Ian and Bradley, who are renowned experts in protein design and drug discovery to VantAI’s Scientific Advisory Board,” said Dr. Zachary Carpenter, CEO & Founder, VantAI.
- “By developing and applying generative AI to characterize the complexity of protein interactions within the cell, we can discover previously unrecognized protein interactions for drug discovery.
Health,
Technology,
Health Technology,
Artificial Intelligence,
Pharmaceutical,
Biotechnology,
Machine learning,
Tufts University,
Doctor of Philosophy,
Research,
IND,
Drug discovery,
SVP,
Media,
Drug development,
Head,
MIT,
Pharmaceutical industry VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery.
Key Points:
- VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery.
- Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.
- Prior to Relay, Cuozzo was Head of Drug Discovery at ZebiAI, a company that applied massive DNA-encoded library datasets to power machine learning for drug discovery.
- As Head of Drug Discovery, Cuozzo will lead drug discovery strategy and technology development to expand the company's research capabilities.
Technology,
Genetics,
Biotechnology,
Training,
Pharmaceutical,
Health,
Science,
Education,
Artificial Intelligence,
Other Science,
Cloud,
Ecosystem,
Cell,
Tissue,
Google Cloud,
GKE,
H100,
Medicine,
NVIDIA,
Drug discovery,
Video game VantAI, a pioneer in generative AI-enabled drug discovery, is working with Google Cloud to power large scale distributed training and further improve internal operations.
Key Points:
- VantAI, a pioneer in generative AI-enabled drug discovery, is working with Google Cloud to power large scale distributed training and further improve internal operations.
- This collaboration is set to provide VantAI with NVIDIA H100 GPUs, a move that VantAI believes will help accelerate the training of geometric foundation models for making protein-protein interactions programmable.
- VantAI's mission to exponentially expand the space of druggable targets by making protein interactions programmable takes a strong leap forward with this collaboration.
- “Google Cloud is committed to providing the most open ecosystem and helping customers accelerate their digital transformations,” said Shweta Maniar, global director of Life Science Strategy & Solutions, Google Cloud.
Retrieved on:
Tuesday, February 13, 2024
Software,
Research,
Other Health,
Pharmaceutical,
Data Management,
Technology,
Genetics,
Artificial Intelligence,
Clinical Trials,
Science,
Biotechnology,
FDA,
Health,
Bristol Myers Squibb,
Therapy,
Protein,
Partnership,
BMY,
PCF,
Drug discovery,
Doctor of Philosophy,
Multimedia,
Intelligence,
Patient,
Pharmaceutical industry VantAI , a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
Key Points:
- VantAI , a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
- Photo credit: VantAI
The collaboration will focus on leveraging VantAI’s generative AI platform to design molecular glues as small molecule therapeutics.
- “At VantAI, we view glue discovery as a challenging ‘geometric puzzle’, and we believe that artificial intelligence is the best tool to find the missing piece.
- Our collaboration with Bristol Myers Squibb is a significant step forward in our journey to use generative AI to accelerate molecular glue discovery and ultimately bring new therapies to patients.”
“This partnership with VantAI reflects our strategy of leveraging predictive sciences to identify novel molecular glues directed toward biologically validated targets,” said Neil Bence, PhD, Vice President, Head of Oncology Discovery, Bristol Myers Squibb.
Retrieved on:
Wednesday, February 7, 2024
Health,
Technology,
Research,
Artificial Intelligence,
Science,
Pharmaceutical,
Biotechnology,
Jae,
Northwestern University,
CFO,
Bristol Myers Squibb,
GSPT1,
Drug discovery,
ADC,
Citigroup,
BBA,
Sale,
Media,
Proximity,
Korea University VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
Key Points:
- VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
- Having led one of the largest deals in induced proximity history, she brings over 15 years of deal making experience to VantAI and its mission.
- As COO/CFO of VantAI, Ms. Kim will oversee the company's operations, including finance, legal and corporate development functions.
- "I am thrilled to join this incredible team at VantAI at this exciting time,” said Ms. Kim.
Software,
Other Health,
General Health,
Networks,
Pharmaceutical,
Data Management,
Technology,
Artificial Intelligence,
Health Technology,
Clinical Trials,
Biotechnology,
Other Technology,
Health,
CSO,
Trust,
Partnership,
Science,
PPI,
Drug discovery,
Disease,
Proteome,
Protein,
Blueprint,
Therapy,
Phosphorylation,
Medicine,
Cell,
Pharmaceutical industry The agreement expands the collaboration initiated in February 2022 to include an additional target program and names VantAI and Blueprint Medicines as the exclusive partners.
Key Points:
- The agreement expands the collaboration initiated in February 2022 to include an additional target program and names VantAI and Blueprint Medicines as the exclusive partners.
- The partnership aims to challenge what is possible in Induced Proximity drug discovery, pursuing targets and molecular mechanisms that have traditionally been considered undruggable, or challenging to modulate, with traditional small molecule or biological therapeutics.
- Proximity modulators, including molecular glues, hetero-bifunctional compounds, and protein-protein interaction (PPI) blockers, are specialized small molecules designed to influence how proteins interact within cells.
- Blueprint Medicines has the option, at its sole discretion, to expand the collaboration to include a fourth target program.
Retrieved on:
Friday, September 29, 2023
SAB,
LLM,
United States Air Force Scientific Advisory Board,
Intelligence,
Proteome,
Associate,
Assistant,
Machine learning,
FMP,
Drug discovery,
EPFL,
AI,
Laboratory,
Proximity,
Medical device NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- VantAI, a leading company focused on the application of artificial intelligence to drug discovery, today announced its newly formed Scientific Advisory Board (SAB).
Key Points:
- NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- VantAI, a leading company focused on the application of artificial intelligence to drug discovery, today announced its newly formed Scientific Advisory Board (SAB).
- A world expert in computational protein design, Dr. Correia pioneered the use of protein surface representations together with VantAI Chief Scientist Michael Bronstein.
- Dr. Liu joins the team to assist VantAI in translating this data-rich view of the proteome into induced proximity drug discovery.
- “VantAI is navigating the forefront of AI-driven protein and molecule design, domains I'm deeply invested in,” said Dr. Correia.
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- VantAI, a leader in ML technologies for drug discovery, is excited to announce the appointment of Dr. Michael Bronstein as Chief Scientist in Residence.
Key Points:
- NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- VantAI, a leader in ML technologies for drug discovery, is excited to announce the appointment of Dr. Michael Bronstein as Chief Scientist in Residence.
- Bronstein is the DeepMind Professor of AI at the University of Oxford and an internationally acclaimed scientist with a track record of excellence in geometric deep learning.
- This appointment underscores VantAI’s commitment to innovation in the realm of artificial intelligence (AI) and drug discovery, marking a new chapter in VantAI’s continued effort to drive generative AI capabilities in induced proximity drug discovery.
- “We are thrilled to have Michael join the VantAI team” said Zach Carpenter, VantAI’s Chief Executive Officer.
Retrieved on:
Wednesday, April 20, 2022
Deep learning,
Proximity,
CEO,
ML,
Solution,
Boehringer Ingelheim,
Organization,
GLOBE,
Program,
Time,
Roivant Sciences,
Fine chemical NEW YORK and INGELHEIM, Germany, April 20, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an early discovery research collaboration focused on degrading traditionally undruggable targets.
Key Points:
- NEW YORK and INGELHEIM, Germany, April 20, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an early discovery research collaboration focused on degrading traditionally undruggable targets.
- The collaboration will initially focus on one degrader program combined with multiple proprietary E3 ligase platforms.
- In addition, Boehringer Ingelheim has exclusive commercial licenses to the degraders that are developed for the initial target under this agreement and will be responsible for global development and commercialization.
- VantAI leverages the cell's most powerful systems through rationally-designed small molecule proximity inducers - building on nature's blueprint using Deep Learning.
Retrieved on:
Wednesday, April 13, 2022
Deep learning,
Protein,
CEO,
E3,
Janssen,
PCF,
ML,
GLOBE,
Machine learning,
Janssen Pharmaceuticals,
Johnson & Johnson,
Roivant Sciences,
Proximity,
Time,
Pharmaceutical industry,
Fine chemical NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
Key Points:
- NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
- Under the terms of the agreement, VantAI and Janssen will leverage VantAI's geometric deep learning platform to potentially generate novel molecular-glue and hetero-bifunctional, protein degrader drug candidates for important disease targets and collaborate on the discovery and implementation of novel E3 ubiquitin ligase platforms.
- Under the terms of the agreement, the collaboration will initially focus on two degrader programs as well as a novel E3 ligase platform development program.
- In addition, Janssen will receive an exclusive commercial license to all programs under the collaboration and will be responsible for global development and commercialization.
